These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6170431)

  • 1. Effective remission induction of refractory childhood acute nonlymphocytic leukemia by VP-16-213 plus azacitidine.
    Look AT; Dahl GV; Kalwinsky D; Senzer N; Mason C; Rivera G
    Cancer Treat Rep; 1981; 65(11-12):995-9. PubMed ID: 6170431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [VP 16-213 in the treatment of acute leukemia in childhood].
    Esumi N; Arakawa S; Imashuku S
    Gan To Kagaku Ryoho; 1983 Mar; 10(3):848-51. PubMed ID: 6576730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophosphamide/etoposide: effective reinduction therapy for children with acute nonlymphocytic leukemia in relapse.
    Kalwinsky DK; Dahl GV; Mirro J; Look AT
    Cancer Treat Rep; 1985; 69(7-8):887-9. PubMed ID: 4016796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Etoposide (VP 16/NK 171) and cytosine arabinoside combination chemotherapy in refractory childhood leukemia].
    Esumi N; Todo S; Arakawa S; Imashuku S
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):951-8. PubMed ID: 3963859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacitidine and VP-16-213.
    Schiffer CA; DeBellis R; Kasdorf H; Wiernik PH
    Cancer Treat Rep; 1982 Feb; 66(2):267-71. PubMed ID: 6173123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
    Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral etoposide for recurrent/progressive sarcomas of childhood.
    Kebudi R; Görgün O; Ayan I
    Pediatr Blood Cancer; 2004 Apr; 42(4):320-4. PubMed ID: 14966827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-azactidine and zorubicin for patients with previously treated acute nonlymphocytic leukemia: a Cancer and Leukemia Group B pilot study.
    Peterson BA; Bloomfield CD; Gottlieb AJ; Coleman M; Greenberg MS
    Cancer Treat Rep; 1982 Mar; 66(3):563-6. PubMed ID: 6174230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined etoposide and 5-azacitidine in children and adolescents with refractory or relapsed acute nonlymphocytic leukemia: a Pediatric Oncology Group Study.
    Hakami N; Look AT; Steuber PC; Krischer J; Castleberry R; Harris R; Ravindranath Y; Vietti TJ
    J Clin Oncol; 1987 Jul; 5(7):1022-5. PubMed ID: 2439659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies with anthracyclines in pediatric acute nonlymphocytic leukemia.
    Chard RL
    Cancer Treat Rep; 1981; 65 Suppl 4():77-81. PubMed ID: 6179617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
    Tallman MS; Lee S; Sikic BI; Paietta E; Wiernik PH; Bennett JM; Rowe JM
    Cancer; 1999 Jan; 85(2):358-67. PubMed ID: 10023703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
    Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma.
    Konits PH; Van Echo DA; Aisner J; Morris D; Wiernik PH
    Am J Clin Oncol; 1982 Oct; 5(5):515-9. PubMed ID: 6758569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia.
    Mehta J; Powles R; Singhal S; Horton C; Hamblin M; Zomas A; Saso R; Prendiville J; Glynne P; Allford S; Mackay H; Treleaven J
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):18-23. PubMed ID: 8916312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term oral administration of etoposide (VP-16) for the patients with refractory or relapsed acute non-lymphocytic leukemia].
    Koyama S; Saitou H; Kashiwaba M
    Rinsho Ketsueki; 1991 Jul; 32(7):736-42. PubMed ID: 1920837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia.
    Zander AR; Vellekoop L; Spitzer G; Verma DS; Litam J; McCredie KB; Keating M; Hester JP; Dicke KA
    Cancer Treat Rep; 1981; 65(5-6):377-81. PubMed ID: 7016323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.